人福医药：关于奥卡西平缓释片获得美国FDA暂定批准文号的公告

Core Viewpoint - The company announced that its subsidiary, Wuhan Renfulikang Pharmaceutical Co., Ltd., received a tentative approval number from the U.S. Food and Drug Administration (FDA) for Oxcarbazepine extended-release tablets [1] Group 1 - The company holds a 75.33% stake in Wuhan Renfulikang, with plans to acquire 100% ownership based on a future repurchase agreement [1] - The FDA's tentative approval is a significant milestone for the company, potentially enhancing its product portfolio in the U.S. market [1]